DoMore Diagnostics secures NOK 16 mill grant for a new innovation project
From left: Sepp De Raedt, Lao Saal, Madeleine Xuyen Ho, Torbjørn Furuseth, Elisabeth M.J. Klaussen, Goran Kovačević, Andreas Berg Storsve
OSLO – February 25, 2025 – DoMore Diagnostics, a leader in AI and deep learning precision diagnostics for digital pathology, is proud to announce that it has been awarded NOK 16 mill in grant financing by the Research Council of Norway Innovation Project for the Industrial Sector 2024 to support the company in an innovation project based on its digital biomarker Histotype Px® Colorectal and circulating tumor DNA (ctDNA). This project has the potential to become a landmark clinical biomarker trial in colorectal cancer (CRC) ensuring personalized cancer treatment for patients worldwide.
The project “Novel AI-based biomarker to predict minimal residual disease and personalize treatment in colorectal cancer” will assess and validate the prognostic value of Histotype Px® Colorectal digital biomarker alone and in combination with ctDNA in stage II and stage III CRC patients and to develop and validate a new biomarker that will predict minimal residual disease and treatment benefit from H&E-stained tumor slides.
This project will be conducted in collaboration with the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital and leading clinical centers worldwide.
"We are thrilled and honored to receive this grant from the Research Council of Norway, which validates the potential of our AI-driven digital biomarker Histotype Px® CRC to transform colorectal cancer treatment and supports the development of a new and improved algorithm. With the support of globally leading partners, this project represents a significant step toward more precise, personalized cancer care – ensuring that patients receive the most effective treatment based on cutting-edge digital pathology and AI innovation," says Torbjørn Furuseth, CEO and Co-founder in DoMore Diagnostics.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com